netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

Please also refer to the Cancer Drugs Fund list and NHSE interim treatment change options during the COVID pandemic

Where a formulary entry does not detail a medicine’s indications for use, the medicine can be assumed to be approved for all licensed indications.

Formulary approved "off-label" use is detailed separately.

 Details...
08.01  Expand sub section  Cytotoxic drugs
 note  Cytotoxic chemotherapy for malignant disease should only be prescribed by a specialist registrar or consultant with adequate experience in this area
08.01  Expand sub section  Side-effects of cytotoxic drugs
Amifostine injection
Unlicensed Drug Unlicensed
Red
Prevention of cumulative renal toxicity associated with repeated administration of cisplatin 
   
08.01  Expand sub section  Drugs for cytotoxic-induced side-effects
Calcium folinate tabs, injection
View adult BNF View SPC online
Formulary
Red
 
   
Calcium levofolinate injection
View adult BNF View SPC online
Formulary
Red
 
   
Disodium folinate injection
View adult BNF View SPC online
Formulary
Red
 
   
Glucarpidase injection
Restricted Drug Restricted
Red
High Cost Medicine
NHS England

Use in accordance with NHS England Clinical Commissioning Policy (link below)

 
Link  NHSE Commissioning Policy Glucarpidase for the urgent treatment of methotrexate-induced renal dysfunction
   
Mesna tabs, injection
View adult BNF View SPC online
Formulary
Red
 
   
08.01.01  Expand sub section  Alkylating drugs
 note  Use in accordance with local guidelines
Bendamustine injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Approved for use as per indications and criteria in the Cancer Drugs Fund, NICE technology appraisals, and NHS England policies (links below)

 
Link  Clinical commissioning policy: Bendamustine with rituximab for first line treatment of advanced indolent non-Hodgkin’s lymphoma (all ages) (170055P)
Link  Clinical Commissioning Policy: Bendamustine with rituximab for first line treatment of mantle cell lymphoma (all ages) (17088P)
Link  Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) (170054P)
Link  MHRA Jul 2017: Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation
Link  NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
   
Cytotoxic Drug Busulfan tabs
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Carmustine implant
View adult BNF View SPC online
Formulary
Red

 
Link  NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
   
Cytotoxic Drug Chlorambucil tabs
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Cyclophosphamide tabs, injection
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Cyclophosphamide injection (CIDP - off-label)
View adult BNF View SPC online
Restricted Drug Restricted
Red

Approved off-label indication:

Chronic inflammatory demyelinating polyradiculoneuropathy

Prescribing restricted to Dr Hadden in accordance with locally agreed protocol

 
   
Cytotoxic Drug Cyclophosphamide tabs (Anti-GBM vasculitis - off-label)
View adult BNF View SPC online
Formulary
Red

Approved off-label indication:

Anti-GBM vasculitis.

Dose = 2-3 mg/kg daily for 2-3 months, dose reduced in the elderly.

Consultant specialist use only

 
   
Cytotoxic Drug Cyclophosphamide tabs (haemophilia - off-label)
View adult BNF View SPC online
Formulary
Red

Approved off-label indication:

Induction of remission in acquired haemophilia. Dose = 50 mg - 100 mg daily, usual course length 6-8 weeks

Consultant specialist use only

 
   
Cytotoxic Drug Cyclophosphamide tabs (immune checkpoint inhibitor therapy related adverse events - off-label)
View adult BNF View SPC online
Formulary
Red

Approved off-label indication:

Management of immune-related adverse events including pneumonitis in patients treated with immune checkpoint inhibitor therapy

 
   
Cytotoxic Drug Ifosfamide injection
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Lomustine caps
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Melphalan tabs, injection
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Thiotepa injection
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Cyclophosphamide pre-filled syringe 1000mg in 50mL
View adult BNF View SPC online
Unlicensed Drug Unlicensed
Red
Chronic lymphocytic leukaemia; lymphomas; solid tumours 
   
Cytotoxic Drug Carmustine 0.04% ointment
Unlicensed Drug Unlicensed
Red

Treatment of mycosis fungoides.

Continuation of therapy and monitoring is provided by secondary care (PIL available on GTi)

Restricted to Consultant Dermatologists specialising in the treatment of skin tumours only

 
   
Cytotoxic Drug Carmustine injection
Unlicensed Drug Unlicensed
Red
BEAM autograft for lymphoma, uric acid nephropathy, neoplastic disease and metabolic disorders 
   
Cytotoxic Drug Mustine injection
Unlicensed Drug Unlicensed
Red
Haematological emergency for a newly diagnosed patient with bulky lymphoma 
   
08.01.02  Expand sub section  Anthracyclines and other cytotoxic antibiotics to top
 note  Use in accordance with local guidelines
Cytotoxic Drug Bleomycin injection (licensed use)
View adult BNF View SPC online
Formulary
Red

 
   
Cytotoxic Drug Dactinomycin injection
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Daunorubicin injection
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Daunorubicin liposomal injection
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Doxorubicin hydrochloride injection
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Doxorubicin hydrochloride pegylated liposomal injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Approved for use as per NICE Technology Appraisal guidance (see links below)

 
Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
Cytotoxic Drug Epirubicin hydrochloride injection
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Idarubicin hydrochloride caps, injection
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Mitomycin injection
View adult BNF View SPC online
Formulary
Red
For intravenous or intravesical administration, depending on indication, as per manufacturer's instructions 
   
Cytotoxic Drug Mitoxantrone (Mitozantrone) injection
View adult BNF View SPC online
Formulary
Red
 
   
Cytotoxic Drug Pixantrone injection
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England

Approved for use as per NICE Technology Appraisal guidance (see links below)

 
Link  NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma
   
Cytotoxic Drug Bleomycin injection (venous and lymphatic malformations - off-label)
View adult BNF View SPC online
Formulary
Red

Approved off-label indication:

Via intralesional injection for scleropathy of lymphatic and low flow (venous) malformations

  • Consultant interventional radiologist use only
  • Dose depends on lesion size.  Maximum 15,000 units per session
  • Not to exceed maximum lifetime cummulative dose of 360,000 units

 

 
   
08.01.03  Expand sub section  Antimetabolites
 note  Use in accordance with local guidelines
Cytotoxic Drug Azacitidine injection
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
NHS England

CONSULTANT SPECIALISTS ONLY

 
Link  NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
   
Cytotoxic Drug Capecitabine tabs
View adult BNF View SPC online
Formulary
Red
  • First-line for metastatic colorectal cancer
  • Third- or fourth-line for locally advanced or metastatic breast cancer (where previous therapy with anthracyclines and taxanes had failed) 
  • Link  NICE CG81: Advanced breast cancer: diagnosis and treatment
    Link  NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
    Link  NICE TA191: Capecitabine for the treatment of advanced gastric cancer
    Link  NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
       
    Cytotoxic Drug Capecitabine tabs (off-label uses)
    View adult BNF View SPC online
    Formulary
    Red

    Approved off-label indications:

    • Adjuvant use in pancreatic cancer (with gemcitabine) as per NHSE Commissioning Policy 170101P
    • Unresectable or metastatic pancreatic neuroendocrine tumours (in combination with temozolomide). Follow local protocol for use.
     
    Link  NHSE Clinical Commissioning Policy 170101P: Gemcitabine and capecitabine following surgery for pancreatic cancer (all ages)
       
    Cytotoxic Drug Cladribine injection (haematology oncology )
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    For haematology oncology indications

     
       
    Cytotoxic Drug Cytarabine and daunorubicin (liposomal) injection (Vyxeos®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA 552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
       
    Cytotoxic Drug Cytarabine injection
    View adult BNF View SPC online
    Formulary
    Red
     
       
    Cytotoxic Drug Fludarabine tabs, injection
    View adult BNF View SPC online
    Formulary
    Red

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
       
    Cytotoxic Drug Fluorouracil injection (oncology indications)
    View adult BNF View SPC online
    Formulary
    Red

     
       
    Cytotoxic Drug Gemcitabine injection
    View adult BNF View SPC online
    Formulary
    Red

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA116: Gemcitabine for the treatment of metastatic breast cancer
    Link  NICE TA25:Guidance on the use of gemcitabine for the treatment of pancreatic cancer
       
    Cytotoxic Drug Gemcitabine injection (pancreatic cancer - off-label)
    View adult BNF View SPC online
    Formulary
    Red

    Approved off-label indication:

    Adjuvant use in pancreatic cancer (with capecitabine) as per NHSE Commissioning Policy 170101P

     
    Link  NHSE Clinical Commissioning Policy 170101P: Clinical Commissioning Policy: Gemcitabine and capecitabine following surgery for pancreatic cancer (all ages)
       
    Cytotoxic Drug Mercaptopurine tabs (oncology indications)
    View adult BNF View SPC online
    Formulary
    Red

     
       
    Cytotoxic Drug Methotrexate tabs injection (oncology)
    View adult BNF View SPC online
    Formulary
    Red

    For oncology indications

    Refer to BNF for highlighted cautions for blood count, and gastro-intestinal, liver and pulmonary toxicities

     
       
    Cytotoxic Drug Pemetrexed injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma
    Link  NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer
    Link  NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer
    Link  NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
       
    Cytotoxic Drug Tioguanine tabs
    View adult BNF View SPC online
    Formulary
    Red
     
       
    Cytotoxic Drug Trifluridine–tipiracil tablets
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
       
    08.01.04  Expand sub section  Vinca alkaloids and etoposide
     note  Use in accordance with local guidelines
    Cytotoxic Drug Etoposide caps, injection
    View adult BNF View SPC online
    Formulary
    Red
     
       
    Cytotoxic Drug Vinblastine injection
    View adult BNF View SPC online
    Formulary
    Red
     
       
    Cytotoxic Drug Vincristine injection
    View adult BNF View SPC online
    Formulary
    Red
     
       
    Cytotoxic Drug Vindesine injection
    View adult BNF View SPC online
    Formulary
    Red
     
       
    Cytotoxic Drug Vinorelbine caps, injection
    View adult BNF View SPC online
    Formulary
    Red
     
       
    08.01.05  Expand sub section  Other antineoplastic drugs
     note  Use in accordance with local guidelines
    Abemaciclib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
    Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (CDF)
       
    Alectinib caps
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
       
    Arsenic trioxide injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

    Approved as per licensed dosing, or dosing in the AML17 trial protocol (off-label). Refer to local guidelines and treatment protocols.

     
    Link  NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
       
    Atezolizumab injection (lung cancer indications)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
    Link  NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
       
    Atezolizumab injection (urothelial cancer indications)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF)
    Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
       
    Avelumab injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

     Approved for use as per NICE technology appraisal guidance (see links below)

     
    Link  NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma (CDF)
       
    Axicabtagene ciloleucel cells dispersion for infusion
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

    A minimum of four doses of tocilizumab are required to be available for use in the event of cytokine release syndrome and emergency equipment must be available prior to infusion.

    Refer to SPC for information on management of cytokine release syndrome.

     
    Link  NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (CDF)
       
    Axitinib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
       
    Binimetinib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
       
    Bosutinib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
       
    Brentuximab injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
    Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
    Link  NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
       
    Brigatinib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
       
    Carfilzomib injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  MHRA Aug 2019: Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events
    Link  MHRA Nov 2019: Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus
    Link  NICE TA457: Carfilzomib for previously treated multiple myeloma
       
    Cemiplimab injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (CDF)
       
    Ceritinib caps
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
    Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
       
    Dabrafenib caps
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA 544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
    Link  NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
       
    Dacomitinib caps
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
       
    Durvalumab injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (CDF)
       
    Encorafenib caps
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
       
    Cytotoxic Drug Eribulin injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
       
    Ibrutinib caps
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  MHRA Aug 17: Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections
    Link  NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
    Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia (CDF)
    Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
       
    Idelalisib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
       
    Inotuzumab ozogamicin injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
       
    Ketoconazole tabs
    View adult BNF View SPC online
    Restricted Drug Restricted
    Red

    Approved off-label indication:

    Management of castration refractory prostate cancer

    Dose = 200-400mg three times daily

     
       
    Lutetium (177Lu) oxodotreotide injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
       
    Midostaurin caps
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA523: Midostaurin for untreated acute myeloid leukaemia
       
    Neratinib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
       
    Niraparib caps
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (CDF)
       
    Nivolumab injection (haematological cancer)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link   MHRA Oct 19: Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
    Link  MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
    Link  NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
       
    Nivolumab injection (lung, renal, head and neck and urothelial cancer)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  MHRA Oct 19: Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
    Link  MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
    Link  NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
    Link  NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer (CDF)
    Link  NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer (CDF)
    Link  NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF)
    Link  NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
    Link  NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (CDF)
       
    Nivolumab injection (skin cancer)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  MHRA Oct 19: Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
    Link  MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
    Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
    Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
    Link  NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (CDF)
       
    Olaparib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE technology appraisal guidance (see links below)

     
    Link  NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
    Link  NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (CDF)
       
    Palbociclib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
    Link  NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (CDF)
       
    Panitumumab injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
       
    Panobinostat caps
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
       
    Pegaspargase injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
       
    Pembrolizumab injection (Hodgkin lymphoma)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (CDF)
       
    Pembrolizumab injection (lung cancer indications)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
    Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
    Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
    Link  NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (CDF)
    Link  NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF)
       
    Pembrolizumab injection (skin cancer indications)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
    Link  NICE TA 553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (CDF)
    Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
    Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
       
    Pembrolizumab injection (urothelial cancer indications)
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (CDF)
    Link  NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF)
       
    Pertuzumab injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
    Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
    Link  NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
       
    Ponatinib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  MHRA Apr 2017: Ponatinib (Iclusig▼): risk of vascular occlusive events—updated advice on possible dose reduction
    Link  MHRA Oct 2018: Ponatinib (Iclusig▼): reports of posterior reversible encephalopathy syndrome
    Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
       
    Regorafenib tabs (gastrointestinal stromal tumours)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
       
    Regorafenib tabs (hepatocellular carcinoma)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
       
    Ribociclib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
    Link  NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (CDF)
       
    Rucaparib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (CDF)
       
    Ruxolitinib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
       
    Talimogene laherparepvec injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
       
    Tisagenlecleucel cells dispersion for infusion
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

    A minimum of four doses of tocilizumab are required to be available for use in the event of cytokine release syndrome and emergency equipment must be available prior to infusion.

    Refer to SPC for information on management of cytokine release syndrome.

     
    Link  NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (CDF)
    Link  NICE TA567:Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (CDF)
       
    Trametinib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
    Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
       
    Venetoclax tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia (CDF)
    Link  NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (CDF)
       
    Streptozocin injection
    View adult BNF View SPC online
    Unlicensed Drug Unlicensed
    Red

    Locally advanced and metastatic neuroendocrine tumours (predominantly pancreas but also small/large bowel and lung)

    For named supervising consultants only in accordance with the prescribing protocol and proforma

     
       
    08.01.05  Expand sub section  Amsacrine
    Cytotoxic Drug Amsacrine injection
    View adult BNF View SPC online
    Formulary
    Red
     
       
    08.01.05  Expand sub section  Bevacizumab to top
    Bevacizumab injection (licensed use)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved as per indications in the Cancer Drugs Fund

     
       
    Bevacizumab injection (neurofibromatosis type 2 - off-label)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved off-label indication:

    Treatment of neurofibromatosis type 2

    For consultant specialists in accordance with a nationally commissioned service protocol

     
       
    08.01.05  Expand sub section  Bexarotene
    Bexarotene caps
    View adult BNF View SPC online
    Formulary
    Red
    Use in accordance with LCNDG guidance 
       
    08.01.05  Expand sub section  Bortezomib
    Cytotoxic Drug Bortezomib injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
    Link  NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
    Link  NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
    Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
    Link  NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (CDF)
       
    08.01.05  Expand sub section  Cetuximab
    Cetuximab injection (colorectal cancer)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  MHRA Feb 2014: Cetuximab: Importance of establishing wild type RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer
    Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
       
    Cetuximab injection (head and neck cancer)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
    Link  NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
       
    08.01.05  Expand sub section  Crisantaspase
    Cytotoxic Drug Crisantaspase injection
    View adult BNF View SPC online
    Formulary
    Red

     
       
    Cytotoxic Drug Asparaginase injection
    View adult BNF View SPC online
    Unlicensed Drug Unlicensed
    Red

    Acute lymphoid leukaemia

     
       
    08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
    Cytotoxic Drug Dacarbazine injection
    View adult BNF View SPC online
    Formulary
    Red
     
       
    Cytotoxic Drug Temozolomide caps (licensed use)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
    Link  NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
       
    Cytotoxic Drug Temozolomide caps (pancreatic neuroendocrine tumours - off-label)
    View adult BNF View SPC online
    Restricted Drug Restricted
    Red

    Approved off-label indication:

  • Unresectable or metastatic pancreatic neuroendocrine tumours (in combination with capecitabine). Follow local protocol for use. 
  •    
    Cytotoxic Drug Temozolomide caps (pituitary adenomas - off-label)
    View adult BNF View SPC online
    Restricted Drug Restricted
    Red

    Approved off-label indication:

    Treatment of pituitary adenomas refractory to surgery and radiotherapy

    Initiation restricted to Consultant Endocrinologists who are part of the Trust MDM, in accordance with a treatment protocol at KCH

     
       
    08.01.05  Expand sub section  Erlotinib
    Erlotinib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
    Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
       
    08.01.05  Expand sub section  Hydroxycarbamide
    Cytotoxic Drug Hydroxycarbamide caps, tabs
    View adult BNF View SPC online
    Formulary

    Red Traffic Light Cancer indications

    Amber Traffic Light Non-cancer licensed indications

     
       
    08.01.05  Expand sub section  Imatinab
    Imatinib tabs (licensed commissioned use)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

    Also approved for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) (NHSE commissioned)

     
    Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
    Link  NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
    Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
       
    Imatinib tabs (Graft vs Host Disease - off-label)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved off-label indication:

    Treatment of Graft vs Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation as per NHSE policy (see link below)

     
    Link  NHS England Clinical Commissioning Policy 16069/P: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation
       
    08.01.05  Expand sub section  Ipilimumab
    Ipilimumab injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  MHRA Jan 2019: Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
    Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
    Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
    Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
    Link  NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (CDF)
       
    08.01.05  Expand sub section  Mitotane to top
    Mitotane tabs
    View adult BNF View SPC online
    Restricted Drug Restricted
    Red

    Treatment of patients with:

    • Biochemical or radiological evidence of persistent or relapsed adrenocortical carcinoma
    • Apparent complete resection of adrenocortical carcinoma for adjuvant therapy
     
       
    08.01.05  Expand sub section  Pentostatin
    Cytotoxic Drug Pentostatin injection (Graft vs Host Disease - off-label)
    View adult BNF View SPC online
    Formulary
    Red

    Approved off-label indication:

    Treatment of Graft vs Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation as per NHSE policy (see link below) 

     
    Link  NHS England Clinical Commissioning Policy 16069/P: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation
       
    Cytotoxic Drug Pentostatin injection (licensed use)
    View adult BNF View SPC online
    Formulary
    Red

     
       
    08.01.05  Expand sub section  Platinum compounds
    Cytotoxic Drug Carboplatin injection
    View adult BNF View SPC online
    Formulary
    Red
     
       
    Cytotoxic Drug Cisplatin injection
    View adult BNF View SPC online
    Formulary
    Red
     
       
    Cytotoxic Drug Oxaliplatin injection
    View adult BNF View SPC online
    Formulary
    Red
     
    Link  NICE CG131: Colorectal cancer: diagnosis and management
    Link  NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
       
    08.01.05  Expand sub section  Procarbazine
    Cytotoxic Drug Procarbazine caps
    View adult BNF View SPC online
    Formulary
    Red
     
       
    08.01.05  Expand sub section  Protein kinase inhibitors
    Afatinib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
       
    Cabozantinib caps (Cometriq - thyroid cancer)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
       
    Cabozantinib tablets (Cabometyx - renal carcinoma)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
    Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
       
    Crizotinib caps
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
    Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
    Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (CDF)
       
    Dasatinib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
       
    Everolimus tabs (breast cancer)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
       
    Everolimus tabs (neuroendocrine tumours)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
       
    Everolimus tabs (renal cancer)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved as per NICE TA guidance (see links below)

     
    Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
    Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
       
    Everolimus tabs (seizures associated with tuberous sclerosis complex)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use in refractory seizures associated with tuberous sclerosis complex as per NHS England Polcy (see link below)

     
    Link  NHSE Clinical Commissioning Policy 170093P: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex
       
    Gefitinib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
       
    Lenvatinib caps (hepatocellular carcinoma - Lenvima®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
       
    Lenvatinib caps (renal cancer - Kisplyx®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
       
    Lenvatinib caps (thyroid cancer - Lenvima®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
       
    Nilotinib caps
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
       
    Nintedanib caps (Vargatef® Non-small-cell lung cancer)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
       
    Osimertinib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (CDF)
    Link  NICE TA621: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
       
    Pazopanib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
       
    Sorafenib tablets (Hepatocellular carcinoma)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
       
    Sorafenib tablets (thyroid cancer)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
       
    Sunitinib caps (neuroendocrine tumours)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  MHRA Jan 2011: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
    Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
       
    Sunitinib caps (renal cell, and gastrointestinal stromal tumours)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  MHRA Jan 2011: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
    Link  NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
    Link  NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
       
    Tivozanib caps
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
       
    Vemurafenib tabs
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
       
    08.01.05  Expand sub section  Taxanes to top
    Cytotoxic Drug Cabazitaxel injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
       
    Cytotoxic Drug Docetaxel injection
    View adult BNF View SPC online
    Formulary
    Red
    NHS England

     
    Link  NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
    Link  NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer
       
    Cytotoxic Drug Paclitaxel albumin injection (Abraxane)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
       
    Cytotoxic Drug Paclitaxel injection
    View adult BNF View SPC online
    Formulary
    Red
    NHS England

     
    Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
    Link  NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
       
    08.01.05  Expand sub section  Topoisomerase I inhibitors
    Cytotoxic Drug Irinotecan Hydrochloride injection
    View adult BNF View SPC online
    Formulary
    Red
     
    Link  NICE CG131: Colorectal cancer: diagnosis and management
       
    Cytotoxic Drug Topotecan injection
    View adult BNF View SPC online
    Formulary
    Red

     
    Link  NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
    Link  NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
       
    Cytotoxic Drug Irinotecan hydrochloride (for liver metastases - locoregional delivery via drug eluting beads)
    View adult BNF View SPC online
    Unlicensed Drug Unlicensed
    Red

    For locoregional treatment of liver metastases in colorectal cancer

    100 mg given via drug-eluting beads (DC Bead™ and DC Bead M1™ - Boston Scientific)

     
       
    08.01.05  Expand sub section  Trabectedin
    Cytotoxic Drug Trabectedin injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA185: Trabectedin for the treatment of advanced soft tissue sarcoma
       
    08.01.05  Expand sub section  Trastuzumab
    Cytotoxic Drug Trastuzumab emtansine injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England
    BlueTeq

    Approved for use as per NICE Technology Appraisal guidance (see links below)

     
    Link  NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
       
    Cytotoxic Drug Trastuzumab injection
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Approved for use as per NICE Technology Appraisal guidance (see links below)

    Biosimilar products available, to be prescribed by brand name.

    Contact pharmacy department for advice on brand for routine prescribing if unsure

     
    Link  NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
    Link  NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
       
    08.01.05  Expand sub section  Tretinoin
    Tretinoin caps
    View adult BNF View SPC online
    Formulary
    Red
     
       
     ....
     Non Formulary Items
    Cytotoxic Drug  Azacitidine injection

    View adult BNF View SPC online
    Non Formulary
    Grey

    Not approved for use in SE London for treating acute myeloid leukaemia with more than 30% bone marrow blasts as per NICE Technology appraisal guidance (see link below)

    Link  NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
     
    Eribulin injection

    View adult BNF View SPC online
    Non Formulary
    Grey

    Not approved for use in SE London for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen as per NICE Technology appraisal guidance (see link below)

    Link  NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
     
    Idelalisib tabs

    View adult BNF View SPC online
    Non Formulary
    Grey

    Not approved for use in SE Lonndon for refractory follicular lymphoma as per NICE Technology appraisal guidance (see links below):

    Link  NICE TA604: Idelalisib for treating refractory follicular lymphoma
     
    Necitumumab injection

    View adult BNF View SPC online
    Non Formulary
    Grey

    Not approved for use in SE London for untreated advanced or metastatic squamous non-small-cell lung cancer as per NICE Technology appraisal guidance (see link below)

    Link  NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
     
    Cytotoxic Drug  Pegylated liposomal irinotecan injection

    View adult BNF View SPC online
    Non Formulary
    Grey

    Not approved for use in SE London for treating pancreatic cancer as per NICE Technology appraisal guidance (see link below)

    Link  MHRA Mar 19: Onivyde (irinotecan, liposomal formulations): reports of serious and fatal thromboembolic events
    Link  NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
     
    Vandetanib tabs

    View adult BNF View SPC online
    Non Formulary
    Grey

    Not approved for use in SE London for treating medullary thyroid cancer as per NICE Technology appraisal guidance (see link below)

    Link  NICE TA550: Vandetanib for treating medullary thyroid cancer
     
    Vismodegib caps

    View adult BNF View SPC online
    Non Formulary
    Grey

    Not approved for use in SE London for treating symptomatic metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that is inappropriate for surgery or radiotherapyas per NICE Technology appraisal guidance (see link below)

    Link  NICE TA489: Vismodegib for treating basal cell carcinoma
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to SPCs
    SMC
    Scottish Medicines Consortium
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Red

    Specialist or hospital prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   

    Amber 1

    Treatment can be initiated in primary care after a recommendation from an appropriate specialist  

    Amber 2

    Specialist initiation followed by maintenance prescribing in primary care  

    Amber 3

    Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  

    Green

    Specialist and non-specialist initiation  

    Grey

    Not recommended for prescribing  

    netFormulary